Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Do VCs Prefer Public Biotechs?

This article was originally published in Start Up

Executive Summary

Private biotechs have run into another complication in seeking venture financing as of late: the fact that so many public, and more mature, biotechs have fallen into VCs' price range.

You may also be interested in...

Alta Stays Flexible with New $500 Million Fund

Now, Alta Partners is shifting direction. Rather than raise a fourth early-stage biopharma fund, Alta opted to raise a single $500 million fund, Alta Partners VIII, which it will commit to biopharmaceutical and medical device companies of all stages.

Hope Springs Eternal in Biopharma IPO Pricing but Bad Haircuts Continue

While START-UP first noted an industry-wide tendency to overestimate the prices IPO investors were willing to pay in early 2005, IPOs have regularly fallen short of the anticipated price ever since, with few exceptions.


Related Companies

Related Deals




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts